, Tracking Stock Market Picks
Enter Symbol:

up 43.83 %

ARDEA BIOSCIENCES (RDEA) rated Buy with price target $40 by Brean Murray

Posted on: Friday,  Dec 10, 2010  8:25 AM ET by Brean Murray

Brean Murray rated Buy ARDEA BIOSCIENCES (NASDAQ: RDEA) on 12/10/2010, when the stock price was $21.97. Since then, ARDEA BIOSCIENCES
has gained 43.83% of its value until Brean Murray rated RDEA Hold on 04/23/2012, when the price was $31.60.
If you would have followed this Brean Murray's recommendation on RDEA, you would have gained 43.83% of your investment in 500 days.

Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/23/2012 10:25 AM Hold
as of 12/31/2010
1 Week down  -0.80 %
1 Month up  16.01 %
3 Months up  12.13 %
1 YTD up  84.21 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/10/2010 8:25 AM Buy
21.97 40.00
11/8/2010 1:25 PM Buy
24.02 35.00
4/1/2010 10:25 AM Buy
22.56 28.00
12/3/2009 8:25 AM Buy
14.81 19.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy